KALV - CIK 0001348911
The table below shows KalVista Pharmaceuticals, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $213.77M | $243.50M | $41.58M | $31.85M | $23.06M | $57.67M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | $4.00M | $458.00K | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $314.20M |
| $325.23M |
| $152.27M |
| $191.63M |
| $104.10M |
| $128.61M |
| Property, plant & equipment | $2.84M | $3.19M | $2.04M | $2.10M | $2.42M | $2.50M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $328.92M | $339.93M | $160.83M | $200.20M | $113.97M | $138.74M |
| Accounts payable | $8.04M | $8.07M | $5.20M | $10.79M | $3.10M | $4.90M |
| Total current liabilities | $60.82M | $45.07M | $22.16M | $22.41M | $19.13M | $17.75M |
| Long-term debt | $172.21M | - | - | - | - | - |
| Total liabilities | $348.57M | $322.93M | - | - | - | - |
| Retained earnings | -$786.18M | -$739.10M | -$552.44M | -$510.17M | -$425.08M | -$396.05M |
| Total equity | -$19.65M | $17.00M | $133.99M | $172.80M | $88.58M | $114.45M |